Last 46 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.39 | — | — | — | — | — | 0.53 | 1.31 | 0.21 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 191.61 | 282.12 | 182.33 | 24.62 | 464.50 | 452.37 | 1183.36 | 175.73 | 13.73 | 1.90 | 4.61 | 7.88 | 10.42 | 64.09 | 20.33 | 101.26 | 253.92 | — | 150.75 | 177.05 | 889.30 |
| — | -37.6% | -84.6% | -86.0% | +3282.8% | +23647.7% | +25593.2% | +2130.8% | +31.7% | -97.0% | -77.3% | -92.2% | -95.9% | — | -86.5% | -42.8% | -71.4% | — | — | — | — | |
| P/B Ratio | 0.07 | 1.93 | 0.64 | 0.23 | 0.36 | 0.35 | 0.93 | — | — | — | — | — | — | — | 3.36 | 4.15 | 2.70 | 1.96 | 1.76 | 2.68 | 20.19 |
| — | +458.2% | -30.6% | — | — | — | — | — | — | — | — | — | — | — | +90.7% | +55.1% | -86.6% | -84.3% | -74.2% | — | — | |
| P/FCF | — | — | — | — | — | — | — | 19.53 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | 0.60 | 8.20 | 0.37 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -354.9% | -269.7% | -431.8% | -98.1% | -1000.0% | -583.3% | -887.5% | -380.0% | -38.7% | -101.3% | -72.7% | -53.6% | -124.9% | -915.1% | -201.8% | -1344.6% | -2039.5% | — | -95.2% | -47.0% | 28.0% |
| — | +53.8% | +51.3% | +74.2% | -2487.0% | -475.7% | -1121.2% | -609.3% | +69.1% | +88.9% | +64.0% | +96.0% | +93.9% | — | -111.9% | -2760.9% | -7383.8% | — | — | — | — | |
| Operating Margin | -30712.7% | -21278.8% | -36522.7% | -13082.7% | -96880.0% | -78583.3% | -68075.0% | -51870.0% | -1162.4% | -1397.8% | -1389.7% | -1561.8% | -1963.1% | -9930.1% | -4574.2% | -21965.2% | -30746.1% | — | -10388.9% | -6559.7% | -6834.0% |
| — | +72.9% | +46.3% | +74.8% | -8234.1% | -5522.1% | -4798.5% | -3221.2% | +40.8% | +85.9% | +69.6% | +92.9% | +93.6% | — | +56.0% | -234.9% | -349.9% | — | — | — | — | |
| Net Margin | 564.8% | -16315.2% | -272.7% | -2428.8% | -107660.0% | -198683.3% | 237100.0% | 14310.0% | 6465.8% | -1105.9% | -1506.1% | -1338.0% | -2234.0% | -8757.2% | -4020.4% | -18267.9% | -34376.3% | — | -8927.0% | -5739.3% | -6113.5% |
| — | +91.8% | -100.1% | -117.0% | -1765.1% | -17865.4% | +15842.2% | +1169.5% | +389.4% | +87.4% | +62.5% | +92.7% | +93.5% | — | +55.0% | -218.3% | -462.3% | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.3% | -24.3% | -0.3% | -5.3% | -18.8% | -33.0% | 111.9% | — | — | — | — | — | — | -291.5% | -165.0% | -103.6% | -74.7% | -48.1% | -23.4% | -30.0% | -31.6% |
| — | +26.2% | -100.2% | — | — | — | — | — | — | — | — | — | — | -506.0% | -604.8% | -245.0% | -136.0% | -88.9% | +41.0% | — | — | |
| ROA | 1.2% | -12.6% | -0.1% | -3.3% | -13.1% | -24.7% | 45.4% | 4.7% | 184.1% | -28.2% | -43.2% | -37.4% | -36.9% | -24.4% | -30.1% | -32.4% | -33.7% | -30.6% | -19.7% | -26.5% | -27.1% |
| — | +49.0% | -100.3% | -170.3% | -107.1% | +12.7% | +205.1% | +112.5% | +598.5% | -15.6% | -43.8% | -15.4% | -9.5% | +20.2% | -52.7% | -22.1% | -24.6% | -31.7% | +25.7% | +54.1% | +52.2% | |
| ROIC | -56.6% | -15.5% | -17.3% | -15.4% | -10.6% | -8.4% | -11.5% | -16.1% | -56.6% | -216.8% | -243.6% | -192.9% | -130.7% | -116.8% | -162.3% | -203.6% | -182.8% | -297.2% | -573.3% | -55695.3% | — |
| — | -84.1% | -50.6% | +3.9% | +81.3% | +96.1% | +95.3% | +91.7% | +56.7% | -85.6% | -50.0% | +5.3% | +28.5% | +60.7% | +71.7% | +99.6% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.60 | 0.88 | 0.68 | 0.60 | 0.36 | 0.30 | 0.23 | — | — | — | — | — | — | — | 4.58 | 3.35 | 1.35 | 0.79 | 0.05 | — | — |
| — | +198.3% | +201.6% | — | — | — | — | — | — | — | — | — | — | — | +9849.0% | — | — | — | +637.4% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.17 | 1.19 | 2.02 | 0.17 | 0.40 | 0.52 | 0.37 | 0.06 | 0.06 | 0.57 | 0.54 | 0.45 | 0.60 | 0.85 | 1.07 | 1.07 | 1.48 | 1.82 | 4.06 | 10.93 | 5.38 |
| — | +127.5% | +444.0% | +182.3% | +606.5% | -7.7% | -30.8% | -86.5% | -90.5% | -33.4% | -49.5% | -57.6% | -59.7% | -53.4% | -73.8% | -90.2% | -72.5% | -79.0% | -73.2% | +1069.0% | +1285.4% | |
| Quick Ratio | 0.16 | 1.19 | 2.02 | 0.17 | 0.40 | 0.50 | 0.35 | 0.05 | 0.05 | 0.55 | 0.53 | 0.44 | 0.59 | 0.84 | 1.06 | 1.06 | 1.48 | 1.81 | 4.06 | 10.86 | 5.38 |
| — | +138.8% | +486.4% | +221.9% | +708.2% | -9.1% | -34.3% | -87.9% | -91.5% | -35.2% | -50.5% | -58.3% | -60.4% | -53.4% | -73.8% | -90.2% | -72.5% | -79.1% | -73.2% | +1116.5% | +1283.7% | |
| Interest Coverage | -116.57 | -3298.00 | -353.67 | -550.40 | -750.38 | -3080.00 | 4656.75 | 164.14 | 5060.25 | -1354.82 | -1156.00 | -915.21 | -135.79 | -77.47 | -120.39 | -110.32 | -56.01 | -54.64 | — | -8.00 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PAVM stock.
PAVmed Inc.'s current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
PAVmed Inc.'s current operating margin is -30712.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PAVmed Inc.'s business trajectory between earnings reports.